Spruce Bio­sciences’ stock plum­mets in wake of PhI­Ib flop, biotech to cut staff

Spruce Bio­sciences’ tildac­er­font failed a Phase IIb test in adults with con­gen­i­tal adren­al hy­per­pla­sia (CAH) due to com­pli­ance is­sues, crush­ing its stock $SPRB by as much as 75% pre­mar­ket.

In the 96-pa­tient CAH­melia-203 tri­al, the oral CRF1 re­cep­tor an­tag­o­nist did not meet the pri­ma­ry end­point of change in an­drostene­dione (A4) lev­els at 12 weeks. The com­pa­ny said there was low com­pli­ance with the drug and stan­dard of care glu­co­cor­ti­coid (GC) steroids, with on­ly about half of pa­tients not­ing they were at least 80% com­pli­ant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.